Trial Profile
A Single Blind, Randomised, Multi-centre, Active Controlled, Trial To Evaluate Safety, Tolerability, Pharmacokinetics And Efficacy Of Ceftazidime And Avibactam Compared With Cefepime In Children From 3 Months To Less Than 18 Years Of Age With Complicated Urinary Tract Infections (Cutis)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2022
Price :
$35
*
At a glance
- Drugs Avibactam/ceftazidime (Primary) ; Cefepime
- Indications Urinary tract infections
- Focus Adverse reactions
- Sponsors AstraZeneca; Pfizer
- 18 Jul 2019 Results published in the Pediatric Infectious Disease Journal
- 16 Apr 2019 Results of PK/PD modelling and simulation to support paediatric dosing using data from NCT01893346, NCT02475733 and NCT02497781 trials, presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases
- 24 Apr 2018 Results presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases